Loading...
•
Mar 31, 2020
Kodiak Sciences Q1 2020 Earnings Report
Reported business highlights and financial results.
Key Takeaways
Kodiak Sciences reported its Q1 2020 financial results, highlighting a net loss of $24.4 million, or $0.54 per share. The company ended the quarter with $430.4 million in cash, cash equivalents, and marketable securities. Despite minimal disruption from COVID-19 in ongoing clinical trials, the initiation of the next set of KSI-301 pivotal studies was delayed by one quarter.
Patient missed visit rates in the DAZZLE study are less than 5%, and clinical trial sites continue to enroll new patients.
Kodiak Sciences has over $430 million in cash, cash equivalents, and marketable securities at quarter end.
The initiation of the next set of KSI-301 pivotal studies was delayed by one quarter, from June/July to September/October 2020.
Kodiak intends to conduct two phase 3 studies in DME, one study in wet AMD, one study in RVO, and one study in non-proliferative DR.
Forward Guidance
Kodiak expects to initiate two KSI-301 pivotal Phase 3 randomized head-to-head studies against aflibercept in treatment naïve Diabetic Macular Edema (DME) patients, initiate KSI-301 pivotal Phase 3 randomized head-to-head study against aflibercept in treatment naïve branch Retinal Vein Occlusion (BRVO) and central Retinal Vein Occlusion (CRVO) patients and initiate KSI-301 pivotal Phase 3 randomized study against sham in non-proliferative Diabetic Retinopathy (NPDR) without DME patients.
Positive Outlook
- Initiate two KSI-301 pivotal Phase 3 randomized head-to-head studies against aflibercept in treatment naïve Diabetic Macular Edema (DME) patients
- Initiate KSI-301 pivotal Phase 3 randomized head-to-head study against aflibercept in treatment naïve branch Retinal Vein Occlusion (BRVO) and central Retinal Vein Occlusion (CRVO) patients
- Initiate KSI-301 pivotal Phase 3 randomized study against sham in non-proliferative Diabetic Retinopathy (NPDR) without DME patients
- Present additional Phase 1b data updates throughout 2020 at major medical meetings and/or company organized virtual events with next update planned for July 2020
- Host conference call and webcast to review recent business highlights
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...